<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905330</url>
  </required_header>
  <id_info>
    <org_study_id>MRX-502</org_study_id>
    <secondary_id>2019-001211-22</secondary_id>
    <nct_id>NCT03905330</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)</brief_title>
  <acronym>MARCH-PFIC</acronym>
  <official_title>MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment (maralixibat) is
      safe and effective in pediatric participants with Progressive Familial Intrahepatic
      Cholestasis (PFIC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at multiple sites in North America, Europe, Asia, and South
      America.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response as measured by the mean change in pruritus severity as assessed by the Observer rated Itch Reported Outcome (ItchRO [Obs])</measure>
    <time_frame>Between Baseline and Week 15 through 26</time_frame>
    <description>Compare the average before midday (AM) Observer Itch Reported Outcome (ItchRO[Obs]) pruritus severity score between participants on active treatment versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response as measured by the mean change in pruritus frequency as assessed by the Observer rated Itch Reported Outcome (ItchRO [Obs])</measure>
    <time_frame>Between Baseline and Week 15 through 26</time_frame>
    <description>Compare the average before midday (AM) Observer Itch Reported Outcome (ItchRO[Obs]) pruritus frequency score between participants on active treatment versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in total serum Bile Acids</measure>
    <time_frame>Between Baseline and Week 26</time_frame>
    <description>Compare normalization or reduction in total serum Bile Acids between participants on active treatment versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis (PFIC)</condition>
  <arm_group>
    <arm_group_label>Maralixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maralixibat</intervention_name>
    <description>Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.</description>
    <arm_group_label>Maralixibat</arm_group_label>
    <other_name>Formerly LUM001 and SHP625</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to maralixibat orally twice daily for 26 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Informed consent and assent (as applicable) per Institutional Review Board/Ethics
             Committee (IRB/EC)

          -  Male or female subjects with a body weight ≥ 5.0 kg, who are ≥ 12 months and &lt; 18
             years of age at time of consent

          -  Cholestasis as manifested by total sBA ≥ 3× Upper Limit of Normal (ULN)

          -  An average AM ItchRO(Obs) score ≥ 1.5 during 4 consecutive weeks of the screening
             period, leading to the baseline visit (Visit 1)

          -  Completion of at least 21 valid morning ItchRO(Obs) entries during 4 consecutive weeks
             of the screening period, leading to the baseline visit (Visit 1)

          -  Diagnosis of PFIC based on:

               -  Chronic cholestasis as manifested by persistent (&gt;6 months) pruritus, biochemical
                  abnormalities or pathological evidence of progressive liver disease and

               -  Primary Cohort: Subjects with genetic testing results consistent with biallelic
                  disease-causing variation in ABCB11 (PFIC2), based on standard of care genotyping

               -  Supplemental Cohort: i. Subjects with genetic testing results consistent with
                  biallelic disease-causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or TJP2
                  (PFIC4), based on standard of care genotyping ii. Subjects with PFIC phenotype
                  without a known mutation or with another known mutation not described above iii.
                  Subjects with PFIC after internal or external biliary diversion surgery or for
                  whom internal or external biliary diversion surgery was reversed

        Exclusion Criteria:

          -  Predicted complete absence of bile salt excretion pump (BSEP) function based on the
             type of ABCB11 mutation (PFIC2), as determined by a standard of care genotyping
             (applies to primary cohort only). Subjects can enter the study in the Supplemental
             Cohort (under inclusion criteria 6.ii or 6.iii).

          -  Recurrent intrahepatic cholestasis, indicated by a history of sBA levels &lt;3x ULN or
             intermittent pruritus

          -  Current or recent history (&lt;1 year) of atopic dermatitis or other non-cholestatic
             diseases associated with pruritus

          -  History of surgical disruption of the enterohepatic circulation (applies to primary
             cohort only)

          -  Chronic diarrhea requiring intravenous fluid or nutritional intervention for the
             diarrhea and/or its sequelae at screening or during the 6 months prior to screening

          -  Previous or need for imminent liver transplant

          -  Decompensated cirrhosis (international normalized ratio [INR] &gt; 1.5, and/or albumin &lt;
             30 g/L, history or presence of clinically significant ascites, and/or variceal
             hemorrhage, and/or encephalopathy)

          -  Alanine aminotransferase (ALT) or total serum bilirubin (TSB) &gt; 15× ULN at screening

          -  Presence of other liver disease

          -  Presence of any other disease or condition known to interfere with the absorption,
             distribution, metabolism or excretion of drugs, including bile salt metabolism in the
             intestine (e.g., inflammatory bowel disease), per Investigator discretion

          -  Possibly malignant liver mass on imaging, including screening ultrasound

          -  Known diagnosis of human immunodeficiency virus (HIV) infection

          -  Any prior cancer diagnosis (except for in situ carcinoma) within 5 years of the
             screening visit (Visit 0)

          -  Any known history of alcohol or substance abuse

          -  Administration of bile acids or lipid binding resins, or sodium phenylbutyrate during
             the screening period

          -  Administration of growth hormones at any time before or during the study

          -  Administration of any investigational drug, biologic, or medical device during the
             screening period

          -  Previous use of an ileal bile acid transporter inhibitor (IBATi)

          -  History of non-adherence to medical regimens, unreliability, medical condition, mental
             instability or cognitive impairment that, in the opinion of the Investigator or
             Sponsor medical monitor, could compromise the validity of informed consent, compromise
             the safety of the subject, or lead to nonadherence with the study protocol or
             inability to conduct the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Mirum</last_name>
    <phone>+16506674085</phone>
    <email>clinicaltrials@mirumpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medinfo Mirum</last_name>
    <email>medinfo@mirumpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children Hospital LA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuan-Hao Lin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Rosenthal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine (University of Michigan)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Lopez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University, Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Vittorio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Miethke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Hupertz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Loomes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert H Squires, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VUMC (Vanderbilt University School of Medicine)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynette Gillis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal Aqul, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas, Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen K Mittal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Horslen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel D'Agostino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolf-Dietrich Huber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Cliniques Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Sokal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sírio-Libanês</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilda Porta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta, Edmonton Clinic Health Academy</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Gilmore, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binita Kamath, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardioinfantil</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felipe Ordoñez Gerrero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nowenn Laborde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Gonzales, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Est Hopital, Femme Mère Enfant de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémie Laverdure, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille, Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Roquelaure, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Baumann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antal Dezsőfi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Papa Giovanni XXIII / Unità di Pediatria</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo D'Antiga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico bambino Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manila Canduso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de France, Alfred Naccache</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adib Moukarzel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consultario de Joshue David Covarrubias Esquer</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshue Covarrubias Esquer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik Centrum, Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Czubkowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Kuan Chiou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara University Faculty of Medicine, Turkey</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ceyda Tuna Kirsaçlioğlu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi, Tip Fakultesi</name>
      <address>
        <city>Balçova</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yesim Ozturk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koc University Research Center for Translational Medicine (KUTTAM)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Çiğdem Arikan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deirdre Kelly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Thompson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/progressive-familial-intrahepatic-cholestasis</url>
    <description>Genetics Home Reference - PFIC</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>US FDA Resources</description>
  </link>
  <link>
    <url>https://mirumpharma.com/</url>
    <description>Mirum Pharmaceuticals homepage</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholestasis</keyword>
  <keyword>Maralixibat</keyword>
  <keyword>Mutation</keyword>
  <keyword>PFIC</keyword>
  <keyword>PFIC2</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

